Gynocare update: Modern strategies to improve diagnosis and treatment of rare gynecologic tumors—current challenges and future directions

Date

2021-01-01

Author

Di Fiore, Riccardo
Suleiman, Sherif
Ellul, Bridget
O’toole, Sharon A.
Savona-Ventura, Charles
Felix, Ana
Napolioni, Valerio
Conlon, Neil T.
Erson Bensan, Ayşe Elif
Kahramanoglu, Ilker
Azzopardi, Miriam J.
Dalmas, Miriam
Calleja, Neville
Brincat, Mark R.
Muscat-Baron, Yves
Sabol, Maja
Dimitrievska, Vera
Yordanov, Angel
Vasileva-Slaveva, Mariela
von Brockdorff, Kristelle
Micallef, Rachel A.
Kubelac, Paul
Achimas-Cadariu, Patriciu
Vlad, Catalin
Tzortzatou, Olga
Poka, Robert
Giordano, Antonio
Felice, Alex
Reed, Nicholas
Herrington, C. Simon
Faraggi, David
Calleja-Agius, Jean

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

134
views

0
downloads

More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often based on retrospective studies, expert opinion, or extrapolation from other tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117 (European Network for Gynecological Rare Cancer Research) programme aims to address these challenges by creating a unique network between key stakeholders covering distinct domains from concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials. On this basis, members of this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological Cancer”) have decided to focus their future efforts on the development of new approaches to improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current state-of-the-art and describe the goals of this COST Action and its future challenges with the aim to stimulate discussion and promote synergy across scientists engaged in the fight against this rare cancer worldwide.

URI

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85099822577&origin=inward
https://hdl.handle.net/11511/90883

Journal

Cancers

DOI

https://doi.org/10.3390/cancers13030493

Collections

Department of Biology, Article

Suggestions

OpenMETU
Core

Health-related quality of life of women with endometriosis: An Attachment-Diathesis Model of Chronic Pain perspective Güvenç, İrem Berna; Bozo Özen, Özlem (2023-01-01) Endometriosis is a common gynecological disorder that occurs in women of reproductive age, and negatively affects women’s quality of life. We tested ‘Attachment-Diathesis Model of Chronic Pain’ in a sample of Turkish women with endometriosis by analyzing the paths among attachment styles, pain catastrophizing, coping strategies, and health-related quality of life (HRQoL). Attachment anxiety was related to using less problem-focused coping and seeking more social support, while attachment avoidance was assoc...
Cancer modeling via biologically validated genes Karakelle, Barış Su; Purutçuoğlu Gazi, Vilda; Ürün, Yüksel (2017-05-10) The cancer disease is the second most common disease type seen after the frequency of the cardiovascular diseases. The frequency of this genetic disease changes with respect to the gender. Accordingly, the gynecological cancer, which covers ovarian, endometrial or cervical cancer, is the second most common cancer type in women after the breast cancer. Similar to other cancer types, the gynecological cancer is the system disease, meaning that the malfunctions and mutations in the gene regulatory ...
Multidrug resistance in locally advanced breast cancer Atalay, Can; Gurhan, Ismet Deliloglu; Irkkan, Cigdem; Gündüz, Ufuk (2006-01-01) Background: Advanced breast cancer cases can still be encountered resulting in poor prognosis. The primary treatment for these patients is chemotherapy, and multidrug resistance (MDR) is a serious obstacle in the treatment. Detecting drug resistance before first-line chemotherapy may increase the patient's survival. In this study, the role of MDR is evaluated in locally advanced breast cancer patients. Methods: Reverse transcriptase polymerase chain reaction was used for the detection of MDR genes, ABCB1 an...
Bioinformatic prediction and coexpression network identifies repurposed novel drugs for papillary thyroid cancer Temiz, Kubra (Orta Doğu Teknik Üniversitesi Enformatik Enstitüsü; 2022-10) Thyroid cancer is a type of cancer that affects the endocrine system and has a high malignancy. Papillary thyroid cancer, the most common subtype of thyroid cancer, also has well-differentiated features. Early diagnosed and well-differentiated thyroid cancer is generally associated with a good prognosis and/or survival rate. Therefore, it is of great importance to determine the molecular signatures of the disease. In this study, five papillary thyroid cancer-related gene expression datasets were analyzed us...
Capture and release of viable CTCs in microfluidic channel Ateş, Hatice Ceren; Şen Doğan, Begüm; Özgür, Ebru; Külah, Haluk (null; 2017-10-04) The number of circulating tumor cells (CTCs) in blood is associated with prognosis in several types of cancer. Isolation and characterization of CTCs have important clinical significance in terms of prognosis and early detection of response to treatment. Moreover, downstream characterization of CTCs may help better patient stratification and therapy guidance. However, CTCs are extremely rare and highly sensitive and specific technology is required to isolate viable CTCs from blood cells. In this study, a su...

Citation Formats

R. Di Fiore et al., “Gynocare update: Modern strategies to improve diagnosis and treatment of rare gynecologic tumors—current challenges and future directions,” Cancers, pp. 1–14, 2021, Accessed: 00, 2021. [Online]. Available: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85099822577&origin=inward.